KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Change in Receivables (2017 - 2023)

NovoCure's Change in Receivables history spans 7 years, with the latest figure at -$2.6 million for Q3 2023.

  • For Q3 2023, Change in Receivables rose 77.07% year-over-year to -$2.6 million; the TTM value through Sep 2023 reached -$20.3 million, down 165.17%, while the annual FY2022 figure was -$2.5 million, 51.67% up from the prior year.
  • Change in Receivables for Q3 2023 was -$2.6 million at NovoCure, up from -$6.9 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $19.7 million in Q1 2020 and bottomed at -$14.5 million in Q1 2023.
  • The 5-year median for Change in Receivables is $2.0 million (2019), against an average of $1.8 million.
  • The largest annual shift saw Change in Receivables surged 2242.92% in 2019 before it tumbled 409.23% in 2022.
  • A 5-year view of Change in Receivables shows it stood at $19.5 million in 2019, then tumbled by 116.44% to -$3.2 million in 2020, then surged by 57.96% to -$1.3 million in 2021, then soared by 380.16% to $3.8 million in 2022, then tumbled by 170.06% to -$2.6 million in 2023.
  • Per Business Quant, the three most recent readings for NVCR's Change in Receivables are -$2.6 million (Q3 2023), -$6.9 million (Q2 2023), and -$14.5 million (Q1 2023).